Neumirna Therapeutics ApS: Financial statements 2022
CVR: 41696451
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Neumirna Therapeutics ApS (CVR 41696451) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -4,660,603 and a net result of DKK -5,292,246. Equity in the 2022 report amounted to DKK -3,433,535. The company had 3 employees in the financial year.
- Gross Profit
- DKK -4,660,603
- Profit/Loss
- DKK -5,292,246
- Equity
- DKK -3,433,535
- Total Assets
- DKK 8,972,050
- Employees
- 3
Official annual report
Keep an eye on Neumirna Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of November 9, 2022, Sten Verland has joined the board of directors of Neumirna Therapeutics ApS.
As of November 9, 2022, Mads Spangaard Rasmussen has joined the board of directors of Neumirna Therapeutics ApS.
As of November 8, 2022, Mads Spangaard Rasmussen has left the board of directors of Neumirna Therapeutics ApS.
Neumirna Therapeutics ApS has published its interim report for the period September 21, 2020 to December 31, 2021.
About Neumirna Therapeutics ApS
Neumirna Therapeutics ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ellen Kinson Donnelly. The board consists of Luis Garcia Pareras (chair), Andreas Wallnöfer, Ellen Kinson Donnelly and Francesco Paolo Di Giorgio. The company's owners include HELLERUNG ApS, INVIVO VENTURES III, FCRE and Innovestor Life Science Fund Ky. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK -53,859,865 and a net result of DKK -55,785,767 compared with DKK -6,954,201 the year before. Equity in the 2025 report amounted to DKK 91,816,175.